SN38 ADC Intermediate Linker Design for Stability Without Heavy Metals
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) with camptothecin derivatives face challenges such as poor water-solubility, safety issues due to heavy metal residues, and instability of linkers, leading to reduced efficacy and increased toxicity.
Innovation Solution
A novel antibody-drug conjugate intermediate is developed using a linker structure that avoids heavy metal ions and ensures stability, comprising an alkane or PEG chain with specific substituents, synthesized through a series of controlled reactions to enhance stability and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional methods (DMC or TFA) are used to prepare SN38, then the reaction can proceed, but the yield is low and the process is complex with multiple steps and strict anhydrous requirements
Solution Approach 1:
The patent changes the reaction parameters by using formic acid as both solvent and reagent instead of traditional DMC or TFA systems. This parameter change simplifies the reaction conditions, eliminates the need for strict anhydrous environments, and improves SN38 yield to 90% or above while reducing the number of purification steps required
Solution Approach 2:
The patent extracts and removes the problematic intermediate step involving complex purification and protection/deprotection sequences. By using formic acid directly on irinotecan without requiring intermediate isolation of SN38 hydrochloride, the method eliminates multiple operational steps and reduces overall process complexity
2Productivity
If traditional methods are used, then the reaction can proceed, but the number of steps is large and the process is not efficient
Solution Approach 1:
The patent performs the formylation reaction directly in the formic acid solvent without requiring preliminary activation steps or intermediate isolation. The formic acid is already in its reactive form, eliminating the need for separate activation steps and reducing overall process time while maintaining high efficiency
Solution Approach 2:
The patent merges the reaction and purification steps into a more integrated process. By using formic acid as both solvent and reagent, and by eliminating the need for separate protection/deprotection steps, the method combines multiple operations into fewer steps, improving efficiency and reducing time loss
3Ease of operation
If traditional methods are used, then the reaction can proceed, but the requirements are strict and operation is inconvenient
Solution Approach 1:
The patent uses formic acid, a cheap and readily available reagent, as both solvent and formylating agent. This disposable reagent approach eliminates the need for expensive, sensitive reagents and strict anhydrous conditions, making the operation more convenient and accessible while maintaining reliability
Solution Approach 2:
The patent changes the reaction medium from strict anhydrous conditions to formic acid solvent, which is more tolerant and easier to handle. This parameter change makes the reaction conditions less sensitive to moisture and operational variations, improving ease of operation while maintaining reliable results
4Ease of manufacture
If traditional methods are used, then the reaction can proceed, but the cost is high and the process is not economical
Solution Approach 1:
The patent makes formic acid serve multiple functions simultaneously: as solvent, as formylating reagent, and as a medium that facilitates direct purification. This multi-functionality reduces the need for multiple separate reagents and steps, lowering overall manufacturing cost and reagent consumption while improving economic efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The intermediate improves the stability and safety of ADCs, reducing toxicity and maintaining efficacy by ensuring controlled release of the cytotoxic drug at the tumor site.
Implementation Method 1
formic acid and irinotecan are used as raw materials to prepare an antibody-drug conjugate intermediate SN38
Data Source
Figure 1~2
Figure 3
AI summary
The present disclosure provides an antibody-drug conjugate intermediate containing SN38 and a preparation method thereof, comprising introducing a biologically active water-soluble group PEG into its linker and structurally modifying PEG. The preparation method is simple in steps and cost-saving, and does not introduce heavy metal ions in reactions with higher environmental friendliness. Moreover, the antibody-drug conjugate intermediate synthesized by the preparation method has higher stability and efficacy compared with antibody-drug conjugate intermediates with SN38 as toxin in the prior art.